For women navigating the complexities of breast cancer treatment, reconstructive surgery is often the final, empowering chapter of their recovery journey. Tissue expanders—devices used to stretch the skin and create a pocket for permanent implants—are a standard, reliable technique in this process. However, a significant study published in the February issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS), has shed light on a counterintuitive clinical reality: the very medications designed to prevent infection may, under certain circumstances, be fueling it.
According to new research, patients who undergo a course of antibiotics within 30 days prior to their tissue expander surgery face a nearly four-fold increase in the risk of surgical site infections (SSI). This finding challenges long-held assumptions regarding prophylactic antibiotic use and opens a critical dialogue on the role of the human microbiome in surgical success.
The Core Findings: A Four-Fold Increase in Risk
The study, led by Dr. Bernard T. Lee of Beth Israel Deaconess Medical Center and Harvard Medical School, investigated the correlation between recent antibiotic exposure and post-surgical complications. By utilizing a comprehensive research database, the team isolated two distinct cohorts of 1,383 patients each. One group had received antibiotics within the 30-day window preceding their reconstruction surgery, while the control group had not.
To ensure the integrity of the data, the researchers utilized propensity score matching, balancing both groups across a variety of demographic and clinical variables, including body mass index (BMI), smoking status, age, and breast cancer staging. Despite these controls, the disparity in outcomes was stark. Patients in the “exposed” group were 3.91 times more likely to develop an SSI within the first month following their procedure.
The implications extended beyond simple infection rates. These patients were also twice as likely to experience wound-healing complications, such as dehiscence (the separation of the surgical incision), and faced a significantly higher probability of requiring the surgical removal of the tissue expander device entirely.
A Chronology of Clinical Concern
The journey toward understanding this phenomenon began with an observation that defied conventional medical wisdom. Historically, plastic surgeons have relied on antibiotics as a primary defense against the complications inherent in placing foreign bodies, such as tissue expanders, under the skin. Yet, anecdotal evidence and high rates of infection in clinical practice suggested that these protective measures were failing to provide the expected shield.
Phase 1: The Recognition of "Dysbiosis"
The research team approached the data with the hypothesis that antibiotics might be causing "dysbiosis"—a disruption of the body’s natural, protective bacterial ecosystem. While the human body is colonized by trillions of beneficial bacteria that regulate immune function and provide a barrier against pathogens, broad-spectrum antibiotics do not distinguish between "good" and "bad" bacteria. By wiping out the commensal flora, antibiotics may inadvertently clear the path for more resilient, pathogenic, or drug-resistant bacteria to colonize the surgical site.
Phase 2: The Database Analysis
In the months leading up to the study’s publication, Dr. Lee and his colleagues synthesized records from a vast repository of surgical patients. By tracking antibiotic use through pharmacy records and comparing them against surgical outcomes, the team identified the 30-day window as a high-risk period. This timeframe is significant, as it suggests that the body’s microbiome may require more than a few weeks to recover from the biochemical “reset” triggered by antibiotic therapy.
Phase 3: Longitudinal Observations
One of the most concerning aspects of the study was the persistence of the risk. While the relative risk of infection was highest in the first 30 days, it remained elevated during the 60-to-90-day follow-up period. This suggests that the physiological impact of preoperative antibiotic use is not merely an acute reaction but a prolonged alteration in the patient’s ability to heal and resist opportunistic infections.
Supporting Data and Statistical Significance
The study’s methodology offers a robust defense against critics who might argue that the observed infections were merely a byproduct of the patient’s underlying illness. By employing propensity score matching, the researchers successfully mitigated "selection bias."
For example, a patient with a higher-stage breast cancer or a history of smoking is inherently at higher risk for infection. By matching the “antibiotic-exposed” patients with “control” patients who shared these exact risk profiles, the study ensured that the variable being tested was the antibiotic use itself, not the pre-existing health condition of the patient.
The data revealed a consistent pattern of distress:
- Surgical Site Infection (SSI): A relative risk (RR) of 3.91 in the immediate 30-day post-operative period.
- Wound Dehiscence: Patients were twice as likely to experience wound separation.
- Device Failure: An increased rate of tissue expander explantation, suggesting that when infections do occur, they are often severe enough to require the total abandonment of the reconstruction phase.
- Post-operative Antibiotic Usage: Patients who received preoperative antibiotics were also more likely to be prescribed further antibiotics post-surgery, creating a cyclical, detrimental loop of pharmaceutical intervention.
Official Responses and Clinical Implications
The findings have sparked a quiet but intense debate within the surgical community. Dr. Lee, in his commentary accompanying the publication, noted that while the study does not advocate for an immediate, radical change in clinical practice, it does demand a shift in perspective.
"For plastic surgeons, the findings suggest the need for careful assessment of antibiotic use in patients undergoing tissue expander-based breast reconstruction," Dr. Lee stated. He emphasized that the "potential detrimental consequences of preoperative antibiotic use" are significant enough that surgeons should think twice before prescribing antibiotics for minor, unrelated issues in the weeks preceding a scheduled breast reconstruction.
The Professional Consensus
The American Society of Plastic Surgeons (ASPS) has long emphasized the importance of evidence-based practice. This study serves as a call to action for further investigation. The medical community is currently calling for randomized clinical trials (RCTs) to confirm these findings. RCTs would provide the "gold standard" of evidence by randomly assigning patients to antibiotic or placebo groups, thereby eliminating the remaining variables that a database study—no matter how well-matched—cannot fully account for.
Looking Forward: The Future of Prophylaxis
The implications of this research extend far beyond the field of plastic surgery. If preoperative antibiotics are indeed causing systemic dysbiosis that hinders surgical recovery, the findings could have massive implications for orthopedic, cardiovascular, and general surgery.
The Rise of Probiotics
One of the most promising avenues for future research mentioned by the authors is the use of probiotics. If the goal is to prevent infection, researchers are beginning to ask whether it might be more effective to supplement the microbiome rather than sterilize it. By using targeted probiotics to restore the balance of protective bacteria before surgery, surgeons might theoretically lower the risk of infection without the negative side effects associated with systemic antibiotics.
A Call for Patient Education
For patients, the takeaway is equally important: communication is paramount. Patients preparing for breast reconstruction should ensure their surgical team is fully aware of any antibiotics they have taken in the preceding month, even for seemingly unrelated conditions like dental work, sinus infections, or urinary tract issues.
In conclusion, the study published in Plastic and Reconstructive Surgery serves as a sobering reminder that in the complex theater of the human body, the most common medical interventions carry hidden, systemic costs. As we move toward a more nuanced understanding of the microbiome, the standard of care for breast reconstruction may evolve from a philosophy of "blunt-force protection" to one of "biological preservation."
About Wolters Kluwer
Wolters Kluwer (EURONEXT: WKL) remains a global leader in professional information and software solutions. With 2022 annual revenues of €5.5 billion and operations spanning over 40 countries, the firm provides the data-driven insights that allow medical professionals to make the critical decisions highlighted in this research. For more information, visit www.wolterskluwer.com.
Reference: Lee, B. T., et al. (2024). "Recent Antibiotic Use and Surgical Site Infections in Tissue Expander–Based Breast Reconstruction: A Propensity Score–Matched Analysis." Plastic and Reconstructive Surgery. DOI: 10.1097/PRS.0000000000012333.
About the Author
